Checkpoint inhibitors, specifically antibodies targeting the programed cell-death-1 (PD-1) and its ligand (PD-L1) interactions, have become part of the standard of care for non-small cell lung cancer (NSCLC). Here, CD274 is linked to non-small cell lung carcinoma.